Michelle Madan
Nurse Practitioner · Melbourne, FLNPI 1265415103
Payments from drug & device makers
Across 102 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$661
- Scilex Pharmaceuticals Inc.$395
- Collegium Pharmaceutical, Inc.$244
- Biohaven Pharmaceuticals, Inc.$173
- Teva Pharmaceuticals USA, Inc.$122
- Novo Nordisk$119
- plus $742 from 16 others
What the payments were for
- Food & beverage$2,455100%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $661 |
| Scilex Pharmaceuticals Inc. | 25 | $395 |
| Collegium Pharmaceutical, Inc. | 13 | $244 |
| Biohaven Pharmaceuticals, Inc. | 4 | $173 |
| Teva Pharmaceuticals USA, Inc. | 2 | $122 |
| Novo Nordisk | 1 | $119 |
| Johnson & Johnson | 1 | $112 |
| Vanda Pharmaceuticals Inc. | 1 | $112 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Almatica Pharma LLC | 4 | $82 |
| Lilly USA, LLC | 4 | $61 |
| Amgen | 3 | $53 |
| Redhill Biopharma Inc. | 2 | $47 |
| Pfizer | 2 | $39 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $18 |
| Biodelivery Sciences International, Inc. | 1 | $18 |
| GRT US Holding, Inc. | 1 | $15 |
| Valinor Pharma, LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$230
- NURTEC ODT$124
- RYBELSUS$119
- XARELTO$112
- Fanapt$112
How this compares
$2,455 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 12 | $24,062 |
| Sumatriptan Succinate | 14 | $1,028 |
| Gabapentin | 41 | $876 |
| Tizanidine Hcl | 44 | $625 |
| Celecoxib | 18 | $536 |
| Cyclobenzaprine Hcl | 16 | $224 |
| Buspirone Hcl | 11 | $205 |
| Trazodone Hcl | 11 | $126 |
| Meloxicam | 18 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $39 | $24,06212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Melbourne
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
- Jennifer PuleoTampa$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.